Logo

AURA

Aura Biosciences, Inc.

AURA

Aura Biosciences, Inc. • NASDAQ
$6.60 ▲ 3.45% (+0.22)
Market Cap $419.11 M
52w High $9.53
52w Low $4.34
Dividend Yield 0%
P/E -3.46
Volume 161.98K
Outstanding Shares 63.50M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $27.606M ▼ $-26.13M ▲ 0% $-0.4 ▲ $-25.804M ▲
Q2-2025 $0 $28.313M ▼ $-27.019M ▲ 0% $-0.47 ▲ $-26.671M ▲
Q1-2025 $0 $29.035M ▲ $-27.483M ▼ 0% $-0.55 ▼ $-28.744M ▼
Q4-2024 $0 $27.516M ▲ $-25.834M ▼ 0% $-0.52 ▼ $-25.519M ▼
Q3-2024 $0 $23.232M $-21.042M 0% $-0.42 $-22.919M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $161.866M ▼ $190.024M ▼ $33.357M ▲ $156.667M ▼
Q2-2025 $177.311M ▲ $204.397M ▲ $29.768M ▲ $174.629M ▲
Q1-2025 $127.991M ▼ $155.401M ▼ $27.435M ▼ $127.966M ▼
Q4-2024 $151.094M ▼ $182.503M ▼ $30.533M ▼ $151.97M ▼
Q3-2024 $174.377M $205.34M $30.672M $174.668M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-26.13M ▲ $-20.144M ▲ $-44.019M ▼ $4.363M ▼ $-59.814M ▼ $-20.189M ▲
Q2-2025 $-27.019M ▲ $-20.774M ▲ $19.977M ▼ $69.929M ▲ $69.141M ▲ $-20.813M ▲
Q1-2025 $-27.483M ▼ $-23.355M ▲ $29.813M ▲ $96K ▼ $6.533M ▲ $-23.542M ▲
Q4-2024 $-25.834M ▼ $-23.952M ▼ $29.695M ▲ $543K ▼ $6.286M ▲ $-24.251M ▼
Q3-2024 $-21.042M $-15.273M $9.889M $716K $-4.668M $-15.614M

Five-Year Company Overview

Income Statement

Income Statement Aura is still a pure research‑stage company, so it has no product revenue yet. All the activity you see on the income statement reflects spending on research, clinical trials, and corporate operations rather than sales. Losses have been consistent over the past several years and have gradually increased as development has scaled up. This pattern is typical for an early‑stage biotech that is moving from early clinical work into larger, more expensive trials. The key takeaway: the business is intentionally loss‑making today, with the income statement showing a controlled but persistent cash burn in support of the pipeline.

Balance Sheet

Balance Sheet The balance sheet is small but relatively clean. Assets are mostly cash and equivalents, with very limited physical assets, which is common for a biotech focused on intellectual property and clinical development rather than manufacturing. Shareholders’ equity remains positive but has been shrinking as ongoing losses accumulate. Debt is present but modest, so the company is not heavily leveraged. Overall, Aura appears to rely more on equity funding than borrowing, which reduces financing risk but can lead to ongoing dilution over time. Management has indicated a cash runway into the middle of 2027, which, if accurate, provides a multi‑year window to reach major clinical milestones before new capital is required. That said, the balance sheet will still need to be watched closely as trials advance and spending rises.

Cash Flow

Cash Flow Cash flow is consistently negative, driven almost entirely by operating activities such as R&D and clinical development. There is essentially no cash being generated from operations, which is expected since there are no commercial products yet. Free cash flow is also negative, but capital expenditures are minimal, meaning most cash out the door is going directly into the scientific and clinical programs rather than into buildings or equipment. This is a classic “cash burn to build value” profile. The sustainability of this pattern depends on the existing cash balance and future access to capital. As trials become larger and more complex, the rate of cash use could rise, so the trajectory of the burn rate is an important risk factor.

Competitive Edge

Competitive Edge Aura is trying to build a niche leadership position with a highly focused cancer platform rather than competing broadly across oncology. Its Virus‑Like Drug Conjugate platform is differentiated by very targeted tumor binding, a dual mechanism that both kills tumor cells and stimulates the immune system, and the ability to potentially adapt the technology to multiple solid tumors. The lead program in early‑stage choroidal melanoma targets a space with very limited treatment options and serious trade‑offs around vision loss. This gives Aura a chance to become a first mover in a rare but important indication, supported by favorable regulatory designations like Orphan Drug and Fast Track in the United States. However, Aura is still a small player in a field dominated by large oncology companies. Commercial capabilities are unproven, and success will depend on clinical data, regulatory approvals, and the company’s ability to either build or partner for commercialization and broader pipeline development. Competitive pressure could emerge from other novel modalities targeting the same cancers or patient populations.

Innovation and R&D

Innovation and R&D Innovation is clearly the center of the Aura story. The VDC platform, using virus‑like particles as precise delivery vehicles, is an attempt to solve a long‑standing problem in oncology: how to strike tumors hard while sparing healthy tissue. Belzupacap sarotalocan (bel‑sar) is the flagship program, with an advanced trial underway in ocular melanoma. Its design—local, light‑activated treatment with the goal of preserving vision—offers a distinct clinical profile compared with radiation. Early data have been encouraging but must still be confirmed in larger, late‑stage studies. Beyond the eye, Aura is moving the same technology into non‑muscle invasive bladder cancer and exploring additional solid tumors and ocular indications. This shows ambition to turn a single drug concept into a broader platform. At the same time, the pipeline is still concentrated around one core technology and one lead asset, which makes outcomes of the next few clinical trials especially critical for the company’s future.

Summary

Aura Biosciences looks like a classic clinical‑stage biotech: no revenue, ongoing and intentional losses, and a balance sheet built to support several more years of development rather than near‑term profitability. Financially, the story is about managing cash burn and preserving flexibility while funding increasingly expensive trials. The lack of heavy debt is a positive, but continued progress will depend on maintaining investor and partner support as the company moves through key data readouts. Strategically, Aura’s value proposition rests on a novel and focused cancer platform with potential first‑in‑class status in a rare ocular cancer and expansion into larger markets like bladder cancer. The upside case depends on successful late‑stage trial results and regulatory approvals; the downside risk is that, as with any biotech at this stage, clinical or regulatory setbacks could significantly impact both the science story and the financial picture. Overall, Aura is best viewed as an early‑stage, high‑uncertainty, high‑impact R&D platform with several important clinical milestones over the next few years likely to shape its long‑term trajectory.

NEWS

November 24, 2025 · 4:05 PM UTC

Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference

Read more

November 13, 2025 · 7:00 AM UTC

Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights

Read more

October 2, 2025 · 7:00 AM UTC

Incentive Program for the Conversion of BDRs into Shares

Read more

October 1, 2025 · 5:00 PM UTC

Western Exploration Files Amended NI 43-101 Technical Report for the AURA Gold Silver Project

Read more

September 3, 2025 · 7:00 AM UTC

Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Read more